Russo Eleonora, Nguyen Hung, Lippert Trenton, Tuazon Julian, Borlongan Cesar V, Napoli Eleonora
Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA.
Brain Circ. 2018 Jul-Sep;4(3):84-94. doi: 10.4103/bc.bc_14_18. Epub 2018 Oct 9.
Stroke is a main cause of mortality and morbidity worldwide. Despite the increasing development of innovative treatments for stroke, most are unsuccessful in clinical trials. In recent years, an encouraging strategy for stroke therapy has been identified in stem cells transplantation. In particular, grafting cells and their secretion products are leading with functional recovery in stroke patients by promoting the growth and function of the neurovascular unit - a communication framework between neurons, their supply microvessels along with glial cells - underlying stroke pathology and recovery. Mitochondrial dysfunction has been recently recognized as a hallmark in ischemia/reperfusion neural damage. Emerging evidence of mitochondria transfer from stem cells to ischemic-injured cells points to transfer of healthy mitochondria as a viable novel therapeutic strategy for ischemic diseases. Hence, a more in-depth understanding of the cellular and molecular mechanisms involved in mitochondrial impairment may lead to new tools for stroke treatment. In this review, we focus on the current evidence of mitochondrial dysfunction in stroke, investigating favorable approaches of healthy mitochondria transfer in ischemic neurons, and exploring the potential of mitochondria-based cellular therapy for clinical applications. This paper is a review article. Referred literature in this paper has been listed in the references section. The data sets supporting the conclusions of this article are available online by searching various databases, including PubMed.
中风是全球范围内导致死亡和发病的主要原因。尽管针对中风的创新治疗方法不断发展，但大多数在临床试验中都未取得成功。近年来，干细胞移植已成为一种令人鼓舞的中风治疗策略。特别是，移植细胞及其分泌产物通过促进神经血管单元（神经元、其供应微血管以及神经胶质细胞之间的通讯框架，是中风病理和恢复的基础）的生长和功能，引领中风患者实现功能恢复。线粒体功能障碍最近被认为是缺血/再灌注神经损伤的一个标志。干细胞向缺血损伤细胞转移线粒体的新证据表明，转移健康线粒体是一种可行的缺血性疾病新型治疗策略。因此，更深入地了解线粒体损伤所涉及的细胞和分子机制可能会带来中风治疗的新方法。在本综述中，我们聚焦于中风中线粒体功能障碍的现有证据，研究健康线粒体向缺血神经元转移的有利方法，并探索基于线粒体的细胞疗法在临床应用中的潜力。本文是一篇综述文章。本文引用的文献已列于参考文献部分。支持本文结论的数据集可通过搜索包括PubMed在内的各种数据库在线获取。
